The global immunohistochemistry market is projected to reach USD 3.3 billion by 2026 from USD 2.3 billion in 2021, at a CAGR of 7.7% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases, technological advancements in IHC, and availability of reimbursements for IHC tests. However, the high degree of consolidation in the by the major market players is expected to restrain the growth of this market during the forecast period.
Leading market players
The global immunohistochemistry market is highly competitive. Prominent players operating in the global immunohistochemistry market include F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US). The key players in this market are increasingly focusing on strategic expansions, partnerships, and product launches and approvals to expand their product and geographic footprint and increase market presence.
F. Hoffmann-La Roche AG (Roche) is a global biotechnology company engaged in the development and manufacturing of pharmaceutical and diagnostic products. The company operates through two major divisions or segments, namely, Pharmaceuticals and Diagnostics. The Diagnostics division consists of the four business areas: Centralized and Point of Care Solutions, Molecular Diagnostics, Tissue Diagnostics, and Diabetes Care. The company provides a range of immunohistochemistry products through the Tissue Diagnostics segment. The company has a presence across Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America.
Danaher Corporation is a global science and technology company that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company operates through three business segments, namely, Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Diagnostics segment provides clinical instrumentation, test consumables, and software to healthcare professionals, and conducts its business through Core Lab Diagnostics, Molecular Diagnostics, Critical Care Diagnostics, and Anatomical Pathology Diagnostics segments. The company offers IHC products through Leica Biosystems, under the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments. Products from these segments include chemical and immuno-staining instruments; reagents; antibodies; consumables; tissue embedding, processing, and slicing instruments; and related reagents and consumables. Slide cover-slipping and slide/cassette marking instruments and imaging instrumentation (including slide scanners) are offered by the company in the field of IHC. The company has its reach in about 60 countries and operates through 261 offices.
Agilent Technologies, Inc. is a leading player in life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow in the fields of food, environmental and forensics, pharmaceutical, diagnostic, chemical & energy, and research. Agilent operates under three business segments—Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Diagnostics and Genomics segment is further segmented into six businesses: Genomics, Nucleic Acid Solutions, Pathology Solutions, Companion Diagnostics, Reagent Partnership, and Biomolecular Analysis. The company offers IHC products through the Pathology Solutions business, focused on cancer diagnostics and anatomic pathology workflows. The company has a presence across North America, Europe, and Asia Pacific. Major countries include the US, the UK, Australia, China, Germany, Italy, Malaysia, Singapore, Belgium, Denmark, Japan, and the Netherlands.
Drivers: The rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases
The increasing geriatric population in developed as well as developing regions will positively influence the growth of the IHC market. With the rapid growth in the geriatric population globally, the prevalence of age-associated diseases is expected to increase significantly. According to the OECD, the number of elderly people living in the US was ~54 million in 2019. Other developed economies around the world also have large and growing geriatric populations. With age, the risk of developing diseases increases proportionately. Thus, the growth in the geriatric population is expected to increase the prevalence of various diseases across the globe. This is considered a key factor driving the growth of the IHC market for diagnostic applications.
Opportunities: Increasing demand for personalized medicine
Personalized medicine for non-small-cell lung cancer patients has proven to be extremely effective, and its use is expected to increase in the future. Immunohistochemistry techniques support this approach to treatment decision-making by performing the most complete and accurate histological subtyping of tumors possible (supported by predictive immunohistochemistry and the assessment of relevant biomarkers). Moreover, the increased availability of immunohistochemistry assays that detect mutant proteins (e.g., BRAF V600E and IDH1 R132H) provides a helpful replacement and/or adjunct for molecular testing. These techniques are highly reproducible, entail reasonable technical and interpretation complexity, and are available at relatively lesser costs, making them valuable novel tools in modern cancer care. The development of multiplex and mutation-specific immunohistochemistry assays represents important innovations, which provide improved utility in the context of personalized medicine and targeted therapy.